Icosavax, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Adam K. Simpson
- Full Time Employees
- 60
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1616 Eastlake Avenue East Seattle WA United States of America 98102
- IPO Date
- Jul 29, 2021
- CIK
- 0001786255
- Website
- icosavax.com
- Similar Companies
- Business
- Icosavax, Inc. is a clinical-stage biotechnology company focused on the development of vaccines designed to prevent infectious diseases through structure-guided vaccine technology. The company's core products and services include the design and development of virus-like particle (VLP) vaccines targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and other respiratory pathogens. Icosavax leverages computational biology and structural virology to create modular vaccines that elicit durable immune responses. Its primary product candidates include intranasal and injectable vaccines aimed at both pediatric and adult populations for prevention of respiratory infections. Icosavax operates primarily in the United States, with its headquarters located in Durham, North Carolina. The company was founded in 2017 and operates in the biotechnology and pharmaceuticals industry, particularly in the vaccine development segment. Its target markets include healthcare providers, pharmaceutical partners, and ultimately patients susceptible to respiratory viral infections. Icosavax focuses on innovative vaccine platforms that may address unmet medical needs in infectious disease prevention. In the past 1-2 years, Icosavax made significant progress with clinical developments, including advancing its vaccine candidates into clinical trials. The company has engaged in strategic partnerships to enhance its vaccine development capabilities and potentially expand its market reach. Icosavax has also completed funding rounds to support its research and development programs and has announced new product candidates as part of expanding its respiratory vaccine pipeline. These recent operational and strategic advances reflect Icosavax's commitment to leveraging cutting-edge science for next-generation vaccines. Overall, Icosavax, Inc. combines advanced structural biology technology with vaccine development to address respiratory diseases, supported by recent clinical progress, partnerships, and funding activities to accelerate its pipeline and commercial readiness. The company's growth trajectory in biotechnology and infectious disease prevention underscores its pivotal role in developing innovative vaccines targeting pressing public health challenges.
ICOSAVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX
ICVX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Icosavax, Inc. Is Fair to Shareholders
ICOSAVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX
ICOSAVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX
Icosavax, Inc. (ICVX) Is Up 0.10% in One Week: What You Should Know
Icosavax, Inc. (ICVX) Moves to Buy: Rationale Behind the Upgrade
Why AstraZeneca Is Buying Icosavax For $1.1 Billion
Shareholder Alert: Ademi LLP investigates whether Icosavax, Inc. has obtained a Fair Price in its transaction with AstraZeneca
ICVX STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Icosavax, Inc. Is Fair to Shareholders
Why Is Icosavax (ICVX) Stock Up 46% Today?
Icosavax surges 45% in pre-market trading as AstraZeneca agrees takeover
AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data
AstraZeneca Will Acquire RSV Vaccine Developer Icosavax For $1.1 Billion
AstraZeneca boosts RSV profile with $1.1bn Icosavax deal
AstraZeneca to buy RSV vaccine maker Icosavax for $1.1 bln
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
Wall Street Analysts Believe Icosavax, Inc. (ICVX) Could Rally 175.87%: Here's is How to Trade
Icosavax, Inc. (ICVX) is on the Move, Here's Why the Trend Could be Sustainable
Icosavax Reports Third Quarter 2023 Financial Results and Provides Corporate Update